Lumos Diagnostics Holdings Ltd. · ASX:LDX
Lumos Diagnostics — Investor Presentation (July 2025)
17 slides from Lumos Diagnostics's investor presentation, Jul 16, 2025
Slide 1: Lumos Diagnostics Holdings Limited Investor Briefing
For personal use only Lumos Diagnostics Holdings Limited Investor Briefing 16 July 2025 Financial information is shown in USD unless otherwise stated. www.lumosdiagnostics.com © Lumos Diagnostics . All rights reserved. 1
Slide 2: Disclaimer and Important Information
Disclaimer and Important Information This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of For personal use
Slide 3: Today's presenters
Today’s presenters For personal use only Doug Ward Barrie Lambert Paul Kase Bob Gergen CEO & Managing Director Chief Financial Officer SVP of Commercial Operations VP of Commercial Operations Lumos Diagnostics Lumos Diagnostics Lumos Diagnostics PHASE Scientific © Lumos Diagnostics . All rights rese
Slide 4: Lumos develops, manufactures and distributes diagnostic products
For personal use only Lumos develops, manufactures and distributes innovative diagnostic products – delivering actionable information, in real time, at the point-of-care. © Lumos Diagnostics , all rights reserved 4
Slide 5: Investment highlights
Investment highlights Proprietary product FebriDx® (bacterial v non-bacterial test) generating sales in market For personal use only Pivotal distribution contract Major agreement signed with PHASE Scientific for the U.S. market - up to US$317 million (A$487 million1) over 6 years,2 assuming FebriDx®
Slide 6: PHASE Scientific partnership
PHASE Scientific partnership A pivotal agreement - one of the largest distribution deals of its type to be done by an ASX-listed point of care diagnostics company For personal use only Exclusive U.S. distribution agreement signed for FebriDx® with PHASE Scientific International Partnership potential
Slide 7: PHASE Scientific exclusive FebriDx U.S. distribution agreement
PHASE Scientific exclusive FebriDx® U.S. distribution agreement Summary of anticipated payments (US$) For personal use only Milestones Payment Timing With CLIA waiver Summary of key terms • Six-year term, with option to extend Exclusivity fee On signing 1.0m • Exclusive rights to distribute and comm
Slide 8: About FebriDx: Lumos' first-of-its-kind point of care test
About FebriDx®: Lumos’ first-of-its-kind point of care test FebriDx® is an aid for healthcare providers to improve patient care and antibiotic stewardship For personal use only The majority of acute respiratory infections are caused by viruses and do not require antibiotics, yet antibiotics are pres
Slide 9: FebriDx addresses a major need: antibiotic overprescription
FebriDx® addresses a major need: antibiotic overprescription ANTIBIOTICS PRESCRIBED (U.S.) ANTIBIOTICS PRESCRIBED IN THE U.S. BY TYPE For personal use only Common cold Sinusitis Other infections Bronchitis Sore throat Ear infection 211M antibiotic prescriptions issued in outpatient settings each yea
Slide 10: FebriDx journey to transform the practice of medicine
FebriDx® journey to transform the practice of medicine Recent achievements forming the critical commercialisation backbone for FebriDx® For personal use only July 2025 Lumos announces major partnership with PHASE Scientific – appointed exclusive U.S. distributor June 2025 Lumos reaches 500th patient
Slide 11: FebriDx CLIA waiver study update
FebriDx® CLIA waiver study update BARDA partnership agreement announced in October 2024 For personal use only • BARDA partnership agreement: non-dilutive funding up to US$8.3 million committed to support CLIA waiver and pediatric studies CLIA waiver clinical study commenced in December 2024 • The CL
Slide 12: FebriDx market opportunity in the U.S. > $1 Billion
FebriDx® market opportunity in the U.S. > $1 Billion A CLIA waiver grant enables facilities (e.g., physician offices, stand alone urgent care centers) to perform diagnostics without laboratory oversight For personal use only MODERATE COMPLEXITY LIMITATION CLIA WAIVER EXPANDS ADDRESSABLE MARKET Poten
Slide 13: Why partner with PHASE Scientific?
Why partner with PHASE Scientific? For personal use only Expertise and understanding of the POC market in the U.S. Highly regarded, well respected commercial leadership Financial commitment to a robust go-to-market launch for FebriDx® Strong network of sub- distributors and end user customers. © Lum
Slide 14: Introducing PHASE Scientific
Introducing PHASE Scientific • Operations in the U.S., mainland China, and Hong Kong For personal use only • Delivering novel diagnostic tools and services for cancer and infectious diseases using proprietary technologies • Products/services: received certifications from the U.S. Food and Drug Admin
Slide 15: PHASE Scientific commercial strategy
PHASE Scientific commercial strategy Contract with National and Regional Med Surg Distributors (3,000+ sales reps) For personal use only Continue to deploy contract sales group MedPro Partners (60 sales reps) Sales strategy with current PHASE call points: ‣ 10 direct sales personnel: Urgent Care, St
Slide 16: Key Priorities
Key Priorities For personal use only Complete CLIA waiver Implement agreement with Initiate the BARDA Deliver on Hologic fFN study and submit PHASE Scientific, drive paediatric study in coming development milestones - application to FDA reimbursement coverage, months - addresses milestone 2 from Pha
Slide 17: Coming roadshow dates and contact
For personal use only Coming roadshow dates: For more information or to arrange a meeting, please contact: 21 July 2025 Brisbane George Kopsiaftis 22 - 23 July 2025 Sydney ir@lumosdiagnostics.com 24 July 2025 Melbourne +61 409 392 687 www.lumosdiagnostics.com © Lumos Diagnostics . All rights reserve
Lumos Diagnostics Holdings — Investor Presentation (July 2025) on 6ix